Scholarlink

<p>More promising, effective, and less-invasive biomarkers for PD(L)-1 targeted responses, immune-related adverse events (irAEs), and prognosis are being explored. We conducted a single-center retrospective study in pan-cancer patients with anti-PD(L)-1 monotherapy. Observational endpoints included treatment response, prognosis, and irAEs. Peripheral blood immunophenotypes were analyzed by Flow Cytometry. 104 patients were enrolled. Higher pretreatment percentages of CD3<sup>+</sup>CD4<sup>+</sup> Th cells were associated with both responses (HR: 6.170, <i>P</i> = 0.034) and prognosis (HR: 1.930, <i>P</i> = 0.022). The higher baseline percentage of CD16<sup>+</sup>CD56<sup>+</sup> NK cells was positively correlated with response (HR: 3.730, <i>P</i> = 0.050) and negatively related to irAEs (HR: 0.460, <i>P</i> = 0.012). Decreased pretreatment CD3<sup>+</sup> T cell counts were related to more irAEs (HR: 0.970, <i>P</i> = 0.026), while the percentage of CD3<sup>+</sup> T cells was negatively associated with prognosis (HR: 1.930, <i>P</i> = 0.022). The higher baseline cell counts of CD3<sup>+</sup>CD8<sup>+</sup> CTL, CD19<sup>+</sup> B, and the percentage of CD19<sup>+</sup> B cells might be related to more irAEs (<i>P</i> &lt; 0.05). Significant correlation between duration of treatment (DOT) and prognosis, irAE and outcome was also confirmed (<i>P</i> &lt; 0.0001). Our findings confirmed multiple baseline circulating immunophenotype characteristics were related to PD(L)-1 targeted response, irAE onset, and prognosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月20日

查看全文
  • Xiaomin Fu,
  • Fanghui Li,
  • Hongqin You,
  • Benling Xu,
  • Tingjie Wang,
  • Peng Qin,
  • Lu Han,
  • Yong Zhang,
  • Fang Zhang,
  • Lingdi Zhao,
  • Baozhen Ma,
  • Yiman Shang,
  • Yonghao Yang,
  • Zibing Wang,
  • Jinrong Qu,
  • Quanli Gao

摘要

More promising, effective, and less-invasive biomarkers for PD(L)-1 targeted responses, immune-related adverse events (irAEs), and prognosis are being explored. We conducted a single-center retrospective study in pan-cancer patients with anti-PD(L)-1 monotherapy. Observational endpoints included treatment response, prognosis, and irAEs. Peripheral blood immunophenotypes were analyzed by Flow Cytometry. 104 patients were enrolled. Higher pretreatment percentages of CD3+CD4+ Th cells were associated with both responses (HR: 6.170, P = 0.034) and prognosis (HR: 1.930, P = 0.022). The higher baseline percentage of CD16+CD56+ NK cells was positively correlated with response (HR: 3.730, P = 0.050) and negatively related to irAEs (HR: 0.460, P = 0.012). Decreased pretreatment CD3+ T cell counts were related to more irAEs (HR: 0.970, P = 0.026), while the percentage of CD3+ T cells was negatively associated with prognosis (HR: 1.930, P = 0.022). The higher baseline cell counts of CD3+CD8+ CTL, CD19+ B, and the percentage of CD19+ B cells might be related to more irAEs (P < 0.05). Significant correlation between duration of treatment (DOT) and prognosis, irAE and outcome was also confirmed (P < 0.0001). Our findings confirmed multiple baseline circulating immunophenotype characteristics were related to PD(L)-1 targeted response, irAE onset, and prognosis.